5 citations
,
October 1990 in “Archives of Dermatology” 
8 citations
,
October 1988 in “Clinics in Dermatology” Current research explores hair growth drugs, while future research aims for personalized treatments.
9 citations
,
October 1988 in “Clinics in Dermatology” Hair loss is caused by genetics and hormones, diagnosed through examination and biopsy, and treated with medications or surgery.
11 citations
,
September 1988 in “Annals of Plastic Surgery” This review from 1988 discussed the use of topical minoxidil for hair growth, noting that about one-third of patients experienced terminal hair growth with a 2 to 3% solution applied twice daily. Treatment needed to last at least six months to assess effectiveness, with better results seen in younger patients, those with thinning hair rather than complete baldness, and those who noticed hair growth within three months. Continued use beyond one year could lead to reduced new hair growth, and stopping the medication often worsened hair loss. Patients with hypertension, cardiovascular disease, or serious systemic illnesses were advised against using minoxidil, and regular monitoring of blood pressure, pulse, electrocardiogram, and serum lipids was recommended.
16 citations
,
July 1988 in “International Journal of Dermatology” A 48-week double-blind study involving 428 patients evaluated the safety and efficacy of a 2% minoxidil solution for treating male pattern baldness. Initially, patients received either the minoxidil solution or a placebo for 24 weeks, after which placebo patients switched to minoxidil. By the end of the placebo-controlled period, 384 patients were evaluable, and 329 completed the study. Results showed that the 2% minoxidil group had a significantly higher mean nonvellus hair count compared to the placebo group (p = 0.0187) and a greater increase in nonvellus hair from baseline to week 24 (p = 0.0385). From weeks 24 to 48, both groups experienced a significant increase in nonvellus hair count. Assessments by patients and investigators indicated significant differences in hair growth between treatments at week 24, with more hair growth observed in the minoxidil group.
23 citations
,
July 1988 in “International Journal of Dermatology” In a 24-week, double-blind, randomized study conducted in The Netherlands, 144 male patients with early male pattern alopecia were treated with either a 2% minoxidil solution or a placebo. The study found that the 2% minoxidil solution was approximately three times more effective than the placebo in increasing hair count and in both investigator and patient subjective evaluations. Minoxidil did not affect systolic and diastolic blood pressures, pulse rate, or body weight, indicating its safety. One patient in the placebo group withdrew due to a skin rash. The study confirmed the safe and effective use of minoxidil for treating early male pattern alopecia.
11 citations
,
January 1987 in “Dermatology” Minoxidil works for 56% of balding men with specific criteria.
13 citations
,
September 1986 in “Archives of Dermatology” Women with more 3α,17β-androstanediol glucuronide compared to sex hormone binding globulin are more likely to have female pattern baldness.
43 citations
,
July 1984 in “Clinical and Experimental Dermatology” Antiandrogen therapy helped increase hair growth in women with hormonal imbalances related to baldness.
90 citations
,
October 1983 in “British Journal of Dermatology” The unit area trichogram is a reliable method to assess hair loss and treatment response in people with androgenic alopecia by measuring hair density and thickness.
6 citations
,
March 1982 in “Clinical and Experimental Dermatology” The document says that hair loss in women is often due to androgenic alopecia, similar to male baldness, and that hirsutism is treated with hormonal and cosmetic methods.
666 citations
,
September 1977 in “British Journal of Dermatology” Common baldness, also known as Androgenetic Alopecia, is caused by a combination of genetic factors and hormones called androgens.
